Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance
[en] 16K prolactin (PRL) is the name given to the 16-kDa N-terminal fragment obtained by proteolysis of rat PRL by tissue extracts or cell lysates, in which cathepsin D was identified as the candidate protease. Based on its antiangiogenic activity, 16K PRL is potentially a physiological inhibitor of tumor growth. Full-length human PRL ( hPRL) was reported to be resistant to cathepsin D, suggesting that antiangiogenic 16K PRL may be physiologically irrelevant in humans. In this study, we show that hPRL can be cleaved by cathepsin D or mammary cell extracts under the same conditions as described earlier for rat PRL, although with lower efficiency. In contrast to the rat hormone, hPRL proteolysis generates three 16K-like fragments, which were identified by N-terminal sequencing and mass spectrometry as corresponding to amino acids 1 - 132 ( 15 kDa), 1 - 147 (16.5 kDa), and 1 - 150 ( 17 kDa). Biochemical and mutagenetic studies showed that the species-specific digestion pattern is due to subtle differences in primary and tertiary structures of rat and human hormones. The antiangiogenic activity of N-terminal hPRL fragments was assessed by the inhibition of growth factor-induced thymidine uptake and MAPK activation in bovine umbilical endothelial cells. Finally, an N-terminal hPRL fragment comigrating with the proteolytic 17-kDa fragment was identified in human pituitary adenomas, suggesting that the physiological relevance of antiangiogenic N-terminal hPRL fragments needs to be reevaluated in humans.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Piwnica, David
Touraine, Philippe
Struman, Ingrid ; Université de Liège - ULiège > Département des sciences de la vie > Biologie et génétique moléculaire
Tabruyn, Sébastien ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Bolbach, Gerard
Clapp, Carmen
Martial, Joseph ; Université de Liège - ULiège > Département des sciences de la vie > GIGA-R : Biologie et génétique moléculaire
Kelly, Paul A
Goffin, Vincent
Language :
English
Title :
Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: Study of their antiangiogenic properties and physiological relevance
Publication date :
October 2004
Journal title :
Molecular Endocrinology
ISSN :
0888-8809
eISSN :
1944-9917
Publisher :
Endocrine Soc, Chevy Chase, United States - Maryland
Clapp C, Sears PS, Russell DH, Richards J, Levay-Young BK, Nicoll CS 1988 Biological and immunological characterization of cleaved and 16K forms of rat prolactin. Endocrinology 122:2892-2898
Clapp C 1987 Analysis of the proteolytic cleavage of prolactin by the mammary gland and liver of the rat: characterization of the cleaved and 16K forms. Endocrinology 121:2055-2064
Corbacho AM, las Escalera GM, Clapp C 2002 Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol 173:219-238
Baldocchi RA, Tan L, King DS, Nicoll CS 1993 Mass spectrometric analysis of the fragments produced by cleavage and reduction of rat prolactin: evidence that the cleaving enzyme is cathepsin D. Endocrinology 133:935-938
Andries M, Tilemans D, Denef C 1992 Isolation of cleaved prolactin variants that stimulate DNA synthesis in specific cell types in rat pituitary cell aggregates in culture. Biochem J 281:393-400
Goffin V, Shiverick KT, Kelly PA, Martial JA 1996 Sequence-function relationships within the expanding family of prolactin, growth hormone, placental lactogen and related proteins in mammals. Endocr Rev 17:385-410
Cooke NE, Coit D, Shine J, Baxter JD, Martial JA 1981 Human prolactin: cDNA structural analysis and evolutionary comparisons. J Biol Chem 256:4007-4016
Clapp C, Martial JA, Guzman RC, Rentier-Del rue F, Weiner RI 1993 The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 133:1292-1299
Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA 1999 Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: novel mechanism for the regulation of angiogenesis. Proc Natl Acad Sci USA 96:1246-1251
D'Angelo G, Struman I, Martial JA, Weiner RI 1995 Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblasts growth factor in capillary endothelial cells is inhibited by the anti-angiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci USA 92:6374-6378
D'Angelo G, Martini JF, Iiri T, Fantl WJ, Martial J, Weiner RI 1999 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol Endocrinol 13:692-704
Martini JF, Piot C, Humeau LM, Struman I, Martial JA, Weiner RI 2000 The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation. Mol Endocrinol 14:1536-1549
Tabruyn SP, Sorlet CM, Rentier-Delrue F, Bours V, Weiner RI, Martial JA, Struman I 2003 The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-κB. Mol Endocrinol 17:1815-1823
Lee H, Struman I, Clapp C, Martial J, Weiner RI 1998 Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression. Endocrinology 139:3696-3703
Clapp C, Weiner RI 1992 A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells. Endocrinology 130: 1380-1386
Goffin V, Binart N, Touraine P, Kelly PA 2002 Prolactin: the new biology of an old hormone. Annu Rev Physiol 64:47-67
Clevenger CV, Furth PA, Hankinson SE, Schuler LA 2003 The role of prolactin in mammary carcinoma. Endocr Rev 24:1-27
Khurana S, Liby K, Buckley AR, Ben-Jonathan N 1999 Proteolysis of human prolactin: resistance to cathepsin D and formation of a nonangiostatic, C-terminal 16K fragment by thrombin. Endocrinology 140:4127-4132
Baldocchi RA, Tan L, Nicoll CS 1992 Processing of rat prolactin by rat tissue explants and serum in vitro. Endocrinology 130:1653-1659
Bernichtein S, Jomain JB, Kelly PA, Goffin V 2003 The N-terminus of human prolactin modulates its biological properties. Mol Cell Endocrinol 208:11-21
Paris N, Rentier-Delrue F, Defontaine A, Goffin V, Lebrun JJ, Mercier L, Martial JA 1990 Bacterial production and purification of recombinant human prolactin. Biotechnol Appl Biochem 12:436-449
Goffin V, Struman I, Mainfroid V, Kinet S, Martial JA 1994 Evidence for a second receptor binding site on human prolactin. J Biol Chem 269:32598-32606
Bernichtein S, Jeay S, Vaudry R, Kelly PA, Goffin V 2003 New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 20:177-190
Volpert O, Luo W, Liu TJ, Estrera VT, Logothetis C, Lin SH 2002 Inhibition of prostate tumor angiogenesis by the tumor suppressor CEACAM1. J Biol Chem 277:35696-35702
Bentzien F, Struman I, Martini JF, Martial J, Weiner R 2001 Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res 61:7356-7362
Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH 2003 Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 63:386-393
Dannies PS 1999 Protein hormone storage in secretory granules: mechanisms for concentration and sorting. Endocr Rev 20:3-21
Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA, Goffin V 2003 Development of pure prolactin receptor antagonists. J Biol Chem 278:35988-35999
Cajero-Juarez M, Avila B, Ochoa A, Garrido-Guerrero E, Varela-Echavarria A, Martinez D, Clapp C 2002 Immortalization of bovine umbilical vein endothelial cells: a model for the study of vascular endothelium. Eur J Cell Biol 81:1-8
Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ 2000 Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34-40
Loukinova E, Dong G, Enamorado-Ayalya I, Thomas GR, Chen Z, Schreiber H, Van Waes C 2000 Growth regulated oncogene-α expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19:3477-3486
Ferrara N, Gerber HP, LeCouter J 2003 The biology of VEGF and its receptors. Nat Med 9:669-676
Cross MJ, Claesson-Welsh L 2001 FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201-207
Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, Wei BY, Stetler-Stevenson WG 2003 TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 114:171-180
Folkman J 1971 Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
Hanahan D, Folkman J 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
Rochefort H, Liaudet-Coopman E 1999 Cathepsin D in cancer metastasis: a protease and a ligand. APMIS 107:86-95
Morikawa W, Yamamoto K, Ishikawa S, Takemoto S, Ono M, Fukushi J, Naito S, Nozaki C, Iwanaga S, Kuwano M 2000 Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 275: 38912-38920
Baldocchi RA, Tan L, Hom YK, Nicoll CS 1995 Comparison of the ability of normal mouse mammary tissues and mammary adenocarcinoma to cleave rat prolactin. Proc Soc Exp Biol Med 208:283-287
Pimenta DC, Oliveira A, Juliano MA, Juliano L 2001 Substrate specificity of human cathepsin D using internally quenched fluorescent peptides derived from reactive site loop of kallistatin. Biochim Biophys Acta 1544:113-122
Keeler C, Dannies PS, Hodsdon ME 2003 The tertiary structure and backbone dynamics of human prolactin. J Mol Biol 328:1105-1121
Powers CA, Hatala MA 1990 Prolactin proteolysis by glandular kallikrein: in vitro reaction requirements and cleavage sites, and detection of processed prolactin in vivo. Endocrinology 127:1916-1927
Galfione M, Luo W, Kim J, Hawke D, Kobayashi R, Clapp C, Yu-Lee LY, Lin SH 2003 Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells. Protein Expr Purif 28:252-258
Sinha YN 1995 Structural variants of prolactin: occurrence and physiological significance. Endocr Rev 16: 354-369
Sinha YN, Gilligan TA, Lee DW, Hollingsworth D, Markoff E 1985 Cleaved prolactin: evidence for its occurrence in human pituitary gland and plasma. J Clin Endocrinol Metab 60:239-243
Warner MD, Sinha YN, Peabody CA 1993 Growth hormone and prolactin variants in normal subjects. Relative proportions in morning and afternoon samples. Horm Metab Res 25:425-429
Fukuoka H, Hamamoto R, Higurashi M 1991 Heterogeneity of serum and amniotic fluid prolactin in humans. Horm Res 35(Suppl 1):58-63
Pellegrini I, Gunz G, Ronin C, Fenouillet E, Peyrat JP, Delori P, Jaquet P 1988 Polymorphism of prolactin secreted by human prolactinoma cells: immunological, receptor binding, and biological properties of the glycosylated and non-glycosylated forms. Endocrinology 122:2667-2674
Corbacho AM, Macotela Y, Nava G, Torner L, Duenas Z, Noris G, Morales MA, Martinez De La Escalera G, Clapp C 2000 Human umbilical vein endothelial cells express multiple prolactin isoforms. J Endocrinol 166:53-62
Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA 1998 Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 83:667-674
Horwitz KB, Mockus MB, Lessey BA 1982 Variant T47D human breast cancer cells with high progesterone-receptor levels despite estrogen and antiestrogen resistance. Cell 28:633-642
Compton MM, Witorsch RJ 1984 Proteolytic degradation and modification of rat prolactin by subcellular fractions of the rat ventral prostate gland. Endocrinology 115: 476-484
Llovera M, Pichard C, Bemichtein S, Jeay S, Touraine P, Kelly PA, Goffin V 2000 Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 19:4695-4705